Bibliography
- Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934) , 1383–1389 (1994).
- Armitage J : The safety of statins in clinical practice.Lancet370(9601) , 1781–1790 (2007).
- Jacobson TA : Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.Am. J. Cardiol.94(9) , 1140–1146 (2004).
- Prueksaritanont T , GorhamLM, MaB et al.: In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s.Drug Metab. Dispos.25(10) , 1191–1199 (1997).
- Neuvonen PJ , NiemiM, BackmanJT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.Clin. Pharmacol. Ther.80(6) , 565–581 (2006).
- Bottorff M , HanstenP: Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism – monograph for physicians.Arch. Intern. Med.160(15) , 2273–2280 (2000).
- Zineh I : HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.Future Cardiol.1(2) , 191–206 (2005).
- Link E , ParishS, ArmitageJ et al.: SLCO1B1 variants and statin-induced myopathy – a genomewide study.N. Engl. J. Med.359(8) , 789–799 (2008).
- Hermann M , BogsrudMP, MoldenE et al.: Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.Clin. Pharmacol. Ther.79(6) , 532–539 (2006).
- Skottheim IB , Gedde-DahlA, HejazifarS, HoelK, AsbergA: Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.Eur. J. Pharm. Sci.33(4–5) , 317–325 (2008).
- Voora D , ShahSH, SpasojevicI et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects.J. Am. Coll. Cardiol.54(17) , 1609–1616 (2009).
- He YJ , ZhangW, ChenY et al.: Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.Clin. Chim. Acta405(1–2) , 49–52 (2009).
- Riedmaier S , KleinK, HofmannU et al.: UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.Clin. Pharmacol. Ther.87(1) , 65–73 (2009).